In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ...

Despite a decline in total revenue, Emergent BioSolutions Inc (EBS) reported a significant increase in net income and ...

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 44.90% and 2.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc.'s revenues are expected to be $1.15 million, up 32.2% from the year-ago quarter. Should You Invest in Emergent Biosolutions Inc. (EBS)? Before you invest in Emergent ...